Terutroban
| Title | Journal |
|---|---|
| Antiplatelet treatment in primary and secondary stroke prevention in women. | European journal of internal medicine 20121001 |
| Why the United States Center for Medicare and Medicaid Services (CMS) should not extend reimbursement indications for carotid artery angioplasty/stenting. | Brain and behavior 20120301 |
| Effects of terutroban, a thromboxane/prostaglandin endoperoxide receptor antagonist, on retinal vascularity in diabetic rats. | Diabetes/metabolism research and reviews 20120201 |
| Asymptomatic and symptomatic carotid stenosis: an obsolete classification? | Stroke research and treatment 20120101 |
| Increased atherothrombotic burden in patients with diabetes mellitus and acute coronary syndrome: a review of antiplatelet therapy. | Cardiology research and practice 20120101 |
| Aging-shifted prostaglandin profile in endothelium as a factor in cardiovascular disorders. | Journal of aging research 20120101 |
| Thromboxane receptors antagonists and/or synthase inhibitors. | Handbook of experimental pharmacology 20120101 |
| Antiplatelet therapy: terutroban does not out-PERFORM aspirin in secondary prevention. | Nature reviews. Cardiology 20110621 |
| Vascular events after stroke: terutroban fails to PERFORM. | Lancet (London, England) 20110611 |
| Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial. | Lancet (London, England) 20110611 |
| Daily administration of the TP receptor antagonist terutroban improved endothelial function in high-cardiovascular-risk patients with atherosclerosis. | British journal of clinical pharmacology 20110601 |
| Design, data management, and population baseline characteristics of the PERFORM magnetic resonance imaging project. | Journal of neurology 20110501 |
| New therapeutic approaches to combat arterial thrombosis: better drugs for old targets, novel targets, and future prospects. | Molecular interventions 20110401 |
| Terutroban, a thromboxane/prostaglandin endoperoxide receptor antagonist, prevents hypertensive vascular hypertrophy and fibrosis. | American journal of physiology. Heart and circulatory physiology 20110301 |
| Placebo - More hatred than love. | Journal of neurosciences in rural practice 20110101 |
| Platelet function in patients with diabetes mellitus: from a theoretical to a practical perspective. | International journal of endocrinology 20110101 |
| Dexmedetomidine induces both relaxations and contractions, via different {alpha}2-adrenoceptor subtypes, in the isolated mesenteric artery and aorta of the rat. | The Journal of pharmacology and experimental therapeutics 20101201 |
| Thromboxane Antagonism with terutroban in Peripheral Arterial Disease: the TAIPAD study. | Journal of thrombosis and haemostasis : JTH 20101101 |
| Controversies and future perspectives of antiplatelet therapy in secondary stroke prevention. | Journal of cellular and molecular medicine 20101001 |
| Terutroban, a thromboxane/prostaglandin endoperoxide receptor antagonist, increases survival in stroke-prone rats by preventing systemic inflammation and endothelial dysfunction: comparison with aspirin and rosuvastatin. | The Journal of pharmacology and experimental therapeutics 20100701 |
| Antiplatelet drugs--do we need new options? With a reappraisal of direct thromboxane inhibitors. | Drugs 20100507 |
| Rationale, design and population baseline characteristics of the PERFORM vascular project: an ancillary study of the Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic attack (PERFORM) trial. | Cardiovascular drugs and therapy 20100401 |
| Pharmacokinetic, pharmacodynamic and clinical profile of novel antiplatelet drugs targeting vascular diseases. | British journal of pharmacology 20100201 |
| [Update on new antithrombotic treatments]. | Revue medicale suisse 20100120 |
| Novel antiplatelet agents in the prevention of cardiovascular complications--focus on ticagrelor. | Vascular health and risk management 20100101 |
| Emerging antiplatelet agents, differential pharmacology, and clinical utility. | Journal of blood medicine 20100101 |
| New antiplatelet agents: why they are needed. | European journal of internal medicine 20091201 |
| New antiplatelet agents. | Current opinion in hematology 20090901 |
| New antiplatelet drugs: beyond aspirin and clopidogrel. | International journal of clinical practice 20090501 |
| Update on oral antiplatelet therapy: principles, problems and promises. | Future cardiology 20090501 |
| Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) study. | Cerebrovascular diseases (Basel, Switzerland) 20090101 |
| The Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic attack (PERFORM) study: baseline characteristics of the population. | Cerebrovascular diseases (Basel, Switzerland) 20090101 |
| TP receptor antagonism: a new concept in atherothrombosis and stroke prevention. | Cerebrovascular diseases (Basel, Switzerland) 20090101 |
| Rationale and design of the Prevention of Cerebrovascular and Cardiovascular Events of Ischemic Origin with Terutroban in Patients with a History of Ischemic Stroke or Transient Ischemic Attack (PERFORM) Study. | Cerebrovascular diseases (Basel, Switzerland) 20090101 |
| Effect of the thromboxane prostaglandin receptor antagonist terutroban on arterial thrombogenesis after repeated administration in patients treated for the prevention of ischemic stroke. | Cerebrovascular diseases (Basel, Switzerland) 20090101 |
| Hypertension and the absence of EDHF-mediated responses favour endothelium-dependent contractions in renal arteries of the rat. | British journal of pharmacology 20080901 |
| Negative effects of rofecoxib treatment on cardiac function after ischemia-reperfusion injury in APOE3Leiden mice are prevented by combined treatment with thromboxane prostanoid-receptor antagonist S18886 (terutroban). | Critical care medicine 20080901 |
| Selective COX-2 inhibitors: new insights into mechanisms of side effects? | Critical care medicine 20080901 |
| Antiplatelet therapy for secondary prevention of noncardioembolic ischemic stroke: a critical review. | Stroke 20080501 |
| Thromboxane receptor activation mediates isoprostane-induced increases in amyloid pathology in Tg2576 mice. | The Journal of neuroscience : the official journal of the Society for Neuroscience 20080430 |
| The role of prostaglandin E and thromboxane-prostanoid receptors in the response to prostaglandin E2 in the aorta of Wistar Kyoto rats and spontaneously hypertensive rats. | Cardiovascular research 20080401 |
| Two isoforms of cyclooxygenase contribute to augmented endothelium-dependent contractions in femoral arteries of 1-year-old rats. | Acta pharmacologica Sinica 20080201 |
| The selective TP receptor antagonist, S18886 (terutroban), attenuates renal damage in the double transgenic rat model of hypertension. | American journal of nephrology 20080101 |
| Altered TP receptor function in isolated, perfused kidneys of nondiabetic and diabetic ApoE-deficient mice. | American journal of physiology. Renal physiology 20080101 |
| Increased spontaneous tone in renal arteries of spontaneously hypertensive rats. | American journal of physiology. Heart and circulatory physiology 20070901 |
| A thromboxane A2/prostaglandin H2 receptor antagonist (S18886) shows high antithrombotic efficacy in an experimental model of stent-induced thrombosis. | Thrombosis and haemostasis 20070901 |
| Renal effects of S18886 (Terutroban), a TP receptor antagonist, in an experimental model of type 2 diabetes. | Diabetes 20070401 |
| Preclinical evaluation of S18886 in an experimental model of coronary arterial thrombosis. | Journal of cardiovascular pharmacology 20061101 |
| TP receptor as a therapeutic target in atherosclerosis and related cardiovascular diseases. | Recent patents on cardiovascular drug discovery 20061101 |
| [Terutroban and endothelial TP receptors in atherogenesis]. | Medecine sciences : M/S 20060401 |
| Thromboxane A2/prostaglandin H2 receptor activation mediates angiotensin II-induced postischemic neovascularization. | Arteriosclerosis, thrombosis, and vascular biology 20060301 |
| The thromboxane receptor antagonist S18886 attenuates renal oxidant stress and proteinuria in diabetic apolipoprotein E-deficient mice. | Diabetes 20060101 |
| Experimental models of thrombosis and atherosclerosis. | Therapie 20060101 |
| The thromboxane A2 receptor antagonist S18886 prevents enhanced atherogenesis caused by diabetes mellitus. | Circulation 20051108 |
| S18886, a selective TP receptor antagonist, inhibits development of atherosclerosis in rabbits. | Atherosclerosis 20051101 |
| Atherosclerosis regression and TP receptor inhibition: effect of S18886 on plaque size and composition--a magnetic resonance imaging study. | European heart journal 20050801 |
| The specific thromboxane receptor antagonist S18886: pharmacokinetic and pharmacodynamic studies. | Journal of thrombosis and haemostasis : JTH 20050701 |
| Antithrombotic properties of the thromboxane A2/prostaglandin H2 receptor antagonist S18886 on prevention of platelet-dependent cyclic flow reductions in dogs. | Journal of cardiovascular pharmacology 20050501 |
| Cyclooxygenases, thromboxane, and atherosclerosis: plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism. | Circulation 20050125 |
| Improved endothelial function by the thromboxane A2 receptor antagonist S 18886 in patients with coronary artery disease treated with aspirin. | Journal of the American College of Cardiology 20030402 |
| S-18886 Servier. | Current opinion in investigational drugs (London, England : 2000) 20020901 |
| Role of prostacyclin in the cardiovascular response to thromboxane A2. | Science (New York, N.Y.) 20020419 |
| Synthesis and biological evaluation of new tetrahydronaphthalene derivatives as thromboxane receptor antagonists. | Bioorganic & medicinal chemistry letters 19980602 |